Prolonged effect of reduced intensity conditioning (RIC) allogeneic transplantation for multiple myeloma on biochemical markers of bone remodelling and osteoclast function: Report of a case

HAEMA

Volumn 7, Issue 1, 2004, Pages 87-91

  Politou, Marianna ^a   Terpos, Evangelos ^a   Nadal, Elizabeth ^a   Crawley, Charles ^a   Apperley, Jane F ^a   Rahemtulla, Amin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bone markers; Multiple myeloma; Osteoprotegerin; Receptor activator of nuclear factor kappa B ligand (RANKL); Reduced intensity conditioning (RIC) allogeneic transplantation

Indexed keywords

BIOCHEMICAL MARKER; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BONE REMODELING; CASE REPORT; CELL ACTIVATION; CELL FUNCTION; CLINICAL FEATURE; DISEASE COURSE; HUMAN; MALE; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION;

EID: 1342346734     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Terpos E, Apperley JF, Samson D, et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 2003; 31: 163-170.
2. Blade J, Vesole DH, Gertz M. Transplantation for multiple myeloma: who, when, how often? Blood 2003; in press.
3. Terpos E, Apperley JF, Samson D, Rahemtulla A. Management of multiple myeloma. Haema 2002; 5: 24-38.
4. Vesole DH, Simic A, Lazarus HM. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts. Bone Marrow Transplant 2001; 28: 725-735.
5. Terpos E, Politou M, Rahemtulla A. New insight in the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003; in press.
6. Clark RE, Flory AJ, Ion EM, et al. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 2000; 96: 2697-2702.
7. Terpos E, Hatziharissi E, Szydlo R, et al. Autologous stem cell transplantation improves abnormal bone turnover in multiple myeloma. Blood 2002; 100: 434a [abstract].
8. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood 2003; 102: 1064-1069.
9. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-2098.
10. Terpos E, de la Fuente J, Szydlo R, et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003; 106: 455-457.
11. Terpos E, Viniou N, de la Fuente J, et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 2003; 70: 34-42.
12. Takamatsu Y, Simmons PJ, Moore RJ, et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 1998; 92: 3465-3473.
13. Ebeling PR, Thomas DM, Erbas B, et al. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 1999; 14: 342-350.